Australian Pharma Stock News

Westpac Banking Corporation has confirmed that Independent Non-Executive Director Peter Nash retired from the Board on 1 July 2026, prompting committee leadership changes, while Richard Heeley has been appointed as incoming Chief Information Officer to replace retiring CIO Scott Collary later this year. These governance and technology leadership shifts highlight Westpac’s ongoing focus on board oversight and modernising its core banking technology capabilities. We’ll now explore how the...

In recent days, EQ Resources has been swept up in stronger investor interest across critical minerals, with tungsten’s role in industrial, defence and manufacturing applications drawing fresh attention to the company’s Australian and Spanish operations. This renewed focus underscores EQ Resources’ position as a Western-linked tungsten supplier amid geopolitical concerns over supply security and growing policy support for critical minerals. With this backdrop of heightened critical minerals...

Gold’s sharp rebound after weaker U.S. private payrolls data and renewed focus on the upcoming nonfarm payrolls report have put precious metals mining stocks back in the spotlight. With markets weighing a possible September U.S. rate hike, softer oil prices easing some inflation worries and the Federal Reserve reaffirming its 2% inflation goal, investors are reassessing how to position around interest rate and commodity price shifts. This article walks through 3 stocks from a Precious Metals...

Geopolitics, new regulations, and a stronger policy push into sustainable investments are reshaping where risks and opportunities sit in the market. With energy routes under pressure and governments aiming to support vulnerable industries and market stability, investors are looking for companies that combine scale, resilience, and exposure to long term sustainability themes. This article uses a Sustainable Investments screener focused on larger companies in clean energy, infrastructure, and...

Objective (ASX:OCL) is back in focus after confirming it will lose the long running Department of Defence ECM agreement. This has prompted a reset of expectations and a closer look at its evolving defence and national security ambitions. See our latest analysis for Objective. The share price reaction has been sharp, with Objective now trading at A$7.80 after a 1 day share price gain of 15.6% that follows a 30 day share price decline of 32.2% and a 1 year total shareholder return decline of...

In recent days, UBS lowered its outlook on PLS Group Limited, a lithium-focused miner whose performance is closely tied to sentiment in the battery materials sector, amid ongoing lithium market volatility and shifting investor expectations. At the same time, PLS Group has continued to advance its growth projects, including pre-final-investment-decision spending of about A$175,000,000 on the P2000 expansion and progress toward restarting the Ngungaju plant, underscoring the tension between...

In late June 2026, Jumbo Interactive attracted renewed investor attention as a technology-focused lottery business with consistent earnings and free cash flow, while Citigroup Global Markets Australia reduced its holding below the substantial shareholder threshold without affecting Jumbo’s operations or guidance. The renewed focus on Jumbo’s software and managed-services growth, particularly its international expansion, highlights how investors are reassessing the company as a...

Equity raising and dividend focus put Acrow in the spotlight Acrow (ASX:ACF) has drawn attention after completing a A$69.58m follow on equity offering at A$0.85 per share, as investors focus on its dividend profile and capital management approach. The offering involved two parcels of ordinary shares, totaling 81,861,697 securities, each priced at A$0.85 with a A$0.02975 discount per share. It also included a subsequent direct listing feature that broadens access to the stock. See our latest...

With inflation trends shifting, central banks reassessing rate paths and growth signals looking mixed, many investors are looking for leaders who are personally tied to the long term success of their companies. Founder led stocks can offer that kind of alignment because the people calling the shots often have much of their own wealth on the line too. This article uses a Founder Led Companies screener that focuses on that commitment. It then highlights 3 stocks from the list that stand out and...

With inflation trends mixed across regions, central banks rethinking rate paths, and labor markets still resilient, many investors are looking beyond headline indices toward higher-upside ideas such as Elite Penny Stocks. The Elite Penny Stocks screener focuses on companies that aim to avoid the classic pitfall of running out of cash, highlighting those with balance sheets that may better support growth plans. For readers hunting for the next potential multi-bagger while keeping an eye on...

Endeavour Group (ASX:EDV) is back in focus as investors react to renewed scrutiny of its growth prospects, with attention on consumer spending pressures, evolving gaming and alcohol regulations, and rising competition across retail and hotels. See our latest analysis for Endeavour Group. At a latest share price of A$3.39, Endeavour Group has seen a 19.37% 30 day share price return and a 5.94% 90 day share price return, yet its 1 year total shareholder return declined 14.97% and its 3 year...

Goodman Group (ASX:GMG) is drawing attention after confirming data centres now account for 73% of its A$14.5b development work in progress, with projects expected to reach about A$18b by June. See our latest analysis for Goodman Group. Against this backdrop, Goodman Group’s recent data centre update comes as the share price has eased over the past week and month, yet remains higher on a 90 day view. The 3 year total shareholder return of 55.81% contrasts with a 1 year total shareholder return...

CSL (ASX:CSL) is back in focus after the European Medicines Agency’s committee recommended revoking the EU marketing authorisation for Tavneos. This has raised fresh questions about the CSL Vifor unit and the stock’s recent recovery. See our latest analysis for CSL. The Tavneos setback arrives after a sharp 27.21% 1 month share price return for CSL. However, this sits against a weaker backdrop, with the stock down 31.52% year to date and the 1 year total shareholder return declining 49.94%,...

Silex Systems (ASX:SLX) is back in focus after completing and beginning commissioning of its laser based Quantum Silicon production plant in Sydney, while interest builds around its nuclear fuel and quantum computing technology platform. See our latest analysis for Silex Systems. Silex Systems' recent commissioning update comes as the stock trades at A$5.71, with a 1 day share price return of 7.74%, a 90 day share price return of 10.44%, and a 5 year total shareholder return that is very...

Neuren Pharmaceuticals (ASX:NEU) is back in focus after the European Medicines Agency's CHMP issued a positive opinion on its Rett syndrome treatment Daybue, clearing the path toward potential approval and European launch. See our latest analysis for Neuren Pharmaceuticals. That CHMP opinion has coincided with a sharp shift in sentiment toward Neuren Pharmaceuticals. The 7 day share price return of 36.82% and 90 day share price return of 46.72% contrast with a year to date share price decline...

Analyst estimates suggest these rare earth stocks may deliver a significant earnings uplift over the next several years.

Elsight Ltd (ASX:ELS), which provides secure connectivity technology for drones and autonomous systems, has recently attracted renewed investor interest as defence and unmanned-sector narratives strengthen globally and its multi-channel communication solutions address critical beyond-visual-line-of-sight data transmission needs across defence, logistics, agriculture, and public safety. An interesting angle is how rising global defence budgets and expanding regulatory acceptance of long-range...

Why this FDA milestone matters for Mesoblast Mesoblast (ASX:MSB) stock is in focus after the US FDA assigned a Biologics License Application filing number for rexlemestrocel-L and accepted a modular review request for patients with LVAD-related risks. This regulatory step, supported by existing Orphan Drug and Regenerative Medicine Advanced Therapy designations, provides formal structure around the approval process for Mesoblast’s late-stage heart failure program and clarifies the path for...

Ramsay Health Care has recently progressed its proposed demerger of European subsidiary Ramsay Santé, alongside reporting stabilising FY25 financial performance despite sector-wide cost pressures. This combination of portfolio simplification and steadier earnings has put Ramsay back in focus as investors reassess the healthcare sector’s fundamentals. We’ll now explore how the Ramsay Santé demerger proposal could reshape Ramsay Health Care’s existing investment narrative and longer-term...

AGL Energy (ASX:AGL) is back in focus after progress on federal environmental assessment for its planned 50MW/100MWh Awaba battery project on the New South Wales Central Coast, which is sharpening attention on the stock’s role in Australia’s renewable transition. See our latest analysis for AGL Energy. Despite the Awaba battery progress putting AGL Energy back in the spotlight, the stock has faced pressure, with the share price down 15.42% over 90 days and the 1 year total shareholder return...

Magellan Financial Group (ASX:MFG) has undergone a sweeping leadership reset, appointing Brian Benari as CEO, Gavin Buchanan as CFO, and reshaping its board with David Gonski AC as chairman and Andrew Formica as deputy chairman. See our latest analysis for Magellan Financial Group. The leadership overhaul has arrived alongside a sharp shift in sentiment around Magellan Financial Group, with the stock showing a 26.60% 30 day share price return and a 28.04% 1 year total shareholder return,...

As the Australian market opens the new financial year with little movement, hovering around 8,780 points, global influences like the U.S.-Iran tensions and tech-driven Wall Street gains continue to shape investor sentiment. Amidst these broader market dynamics, penny stocks remain a compelling area for those seeking investment opportunities in smaller or newer companies. Despite their somewhat outdated name, penny stocks can offer surprising value when backed by solid financials and...

Centuria Capital Group recently completed a A$200,000,000 follow-on equity offering at A$2.00 per stapled security as part of a fully underwritten A$300,000,000 equity raising, alongside confirming a final distribution of A$0.052 per stapled security for the six months to 30 June 2026. The capital raising supports Centuria’s A$454,000,000 acquisition of a 50% interest in Sydney CBD office assets via a new unlisted fund, signalling a meaningful expansion of its Australian office footprint and...

HUB24 Limited has appointed Mr. Andrew Formica as a Non-Executive Director, effective 1 July 2026, adding his 30-plus years of global investment management experience and placing him on the People and Culture, Audit and Nomination Committees. Formica’s concurrent roles at Magellan Financial Group, Barrenjoey and Vinva Holdings mean HUB24’s board now includes a director deeply engaged across multiple parts of the funds management and capital markets ecosystem. We’ll now examine how bringing...